Apologies for the delay in this report. And even if there isn’t much in the way of biotech science to talk about, it’s been an active week for biotech investors. Speaking broadly, the NASDAQ Composite and the biotech indices were generally all singing from the same hymn book, with a 3 — 3.3% improvement for the week. This was enough to return the S&P Biotech composite index to net profit YTD, +1.4%, though still underperforming the year to date performance of the broader market NASDAQ Composite, +$35%.
There is no news on YAHOO for any of the top five performing stocks for the week. For INZY, the +77% return for the week versus its initial price, more than made up for last week when it was the worst stock (-28%), adding to its position as the best performer so far this year, +480%. There was no particular explanation for the week’s worst performer, KZIA, -33%, either. But there WAS a press release on Monday for URGN, which to my eyes looks like a generally positive discussion of the post-approval clinical use of their product to chemically remove certain upper urinary tract tumors, avoiding kidney surgical removal that the previous standard of treatment would call for. But the market didn’t agree, resulting in a drop of -29%, and its designation as the second worst performer for the week.
Looking at the top five contest stocks’ YTD performance, it was a good week for INZY as already discussed. JSPR also had an OK week (+6%), not enough to break into the top five list, but combined with an unfortunate weekly return for CRVS (-15%), was enough for JSPR to return to its second place position in the YTD standings. People paying attention to last week’s report discussion might notice that PTE (3rd worst YTD performer -90%) now uses its “pink sheets” ticker symbol of PTEIQ, after its NASDAQ delisting.
Alas, the contest portfolios performance for the week was, once again, mixed, and on average well below the +3% of the biotech composite indices, dropping another -$500 for both the average and median portfolios. But the top seven portfolios for the week managed to end in the black, with STEVE LOKNESS at the very top, +$5k, outperforming even the S&P biotech index, thanks to 10% positions in both QSI and PACB, the stocks with the second and third best returns for the week. This was a significant improvement in their YTD return to +$34k, but not enough to improve their third place YTD position.
Even the positive return for JSPR, contributing +$12k to YTD second place BLADERUNNER. their other picks cut their return for the week to a barely in the black +$620. But first place ALONER’s 10% position in last place KZIA dragged their weekly return down to -$3.1k, tightening up the gap between them and BLADERUNNER to $7.1k. RKRW’s 10% in URGN meant that the, to me, paradoxical response of the market dropped them from fourth to fifth YTD. The contestant that they change places with, ERIKOTTO, was the other portfolio that chose URGN. The hit on ERIKOTTO was twice as bad from a 20% initial investment in URGN. But they are the only contestant that had the wisdom to invest in INZY, yet only with a 5% position, which compensated for most of the URGN loss, shedding “only” -$510 net for the week, and earning the designation as last week’s “median” portfolio.
This week included the completion on July 11th of the purchase of ISEE for $40 / share. ARTHUR RADLEY was able to take their original $10k stake in ISEE, and see it return $18.7k, ROI of 87%. The cash has been reinvested in the remaining seven stocks in their portfolio.
My portfolio has been sinking into the abyss, in part due to my 20% stake in RVNC and 10% stake in ENTA. Although I don’t think it will implode, it seems unlikely to rise to the surface by the end of the year.
Report Time Ranges
|
|
|
|
|
| From
| To
|
|
|
|
|
|
|
|
| Recent
| 7/7/23
| 7/14/2023
|
|
|
|
|
|
|
|
| YTD
| 12/31/2022
|
|
|
|
| Index Portfolios’ Performance
|
|
|
|
| Symbol
| Recent P/L
| Recent %
| YTD P/L
|
|
|
|
|
|
|
|
| ^IXIC
| $4,327.98
| 3.3%
| $34,846.69
|
|
|
|
|
|
|
|
| ^NBI
| $2,871.43
| 3.0%
| -$2,653.12
|
|
|
|
|
|
|
|
| ^SPSIBI
| $3,203.31
| 3.3%
| $1,428.09
|
|
|
|
| Share Performance
| Recent Performance
| YTD Performance
|
| Top Five
|
| Bottom Five
|
| Top Five
|
| Bottom 5
| Symbol
| P/L / Initial Price
| Symbol
| P/L / Initial Price
| Symbol
| YTD P/L / Initial Price
| Symbol
| YTD P/L/ Initial Price
| INZY
| 77.1%
| KZIA
| -32.7%
| INZY
| 480.0%
| AVTX
| -93.4%
| QSI
| 20.2%
| URGN
| -28.7%
| JSPR
| 191.9%
| APTA.L
| -89.9%
| PACB
| 17.0%
| DCTH
| -25.0%
| CRVS
| 189.4%
| PTEIQ
| -89.5%
| TARA
| 16.0%
| TGTX
| -24.2%
| PRVB
| 136.5%
| PIRS
| -81.3%
| TWST
| 16.0%
| BCDA
| -22.0%
| OMER
| 128.3%
| ALT
| -80.1%
| Average and Median Portfolio Performance
|
| Recent P/L
|
|
|
| YTD P/L
|
|
|
| Avg.
| Median
|
|
|
| Avg
| Median
|
|
|
| -$551.48
| -$508.78
| ERIKOTTO
|
| $3,186.15
| -$3,969.67
| A.J. MULLEN
| Top Seven Portfolio Performances
| Top Recent Performers
| Top YTD Performers
| Contestant (Prev. Rank)
| Recent P/L
| P/L vs. ^SPSIBI
| YTD P/L (Rank)
| Contestant (Prev. Rank)
| YTD P/L
| vs. Top Portfolio
| P/L vs. ^SPSIBI
| Rec. P/L (Rank)
| 1 - STEVE LOKNESS (6)
| $5,117.01
| $1,913.70
| $34,123.84 (3)
| 1 - ALONER (1)
| $49,575.20
| ——
| $48,147.11
| -$3,069.08 (12)
| 2 - A.J. MULLEN (10)
| $3,474.67
| $271.37
| -$3,969.67 (8)
| 2 - BLADERUNNER (2)
| $42,473.82
| $7,101.38
| $41,045.73
| $627.27 (7)
| 3 - JACK HARTMANN (14)
| $1,759.31
| -$1,444.00
| -$3,657.31 (7)
| 3 - STEVE LOKNESS (3)
| $34,123.84
| $15,451.36
| $32,695.75
| $5,117.01 (1)
| 4 - BULBAMAN (13)
| $1,583.99
| -$1,619.32
| -$7,807.19 (11)
| 4 - ERIKOTTO (5)
| $15,043.30
| $34,531.90
| $13,615.20
| -$508.78 (8)
| 5 - ARTHUR RADLEY (5)
| $1,141.49
| -$2,061.82
| $12,883.58 (6)
| 5 - RKRW (4)
| $14,135.91
| $35,439.29
| $12,707.82
| -$4,867.36 (13)
| 6 - TOMATO (15)
| $720.68
| -$2,482.63
| -$4,956.17 (9)
| 6 - ARTHUR RADLEY (6)
| $12,883.58
| $36,691.62
| $11,455.49
| $1,141.49 (5)
| 7 - BLADERUNNER (7)
| $627.27
| -$2,576.04
| $42,473.82 (2)
| 7 - JACK HARTMANN (8)
| -$3,657.31
| $53,232.51
| -$5,085.40
| $1,759.31 (3)
| Top Portfolios’ Contents
| Top Recent Performance Portfolio (STEVE LOKNESS)
| Top YTD Performance Portfolio (ALONER)
| Symbol (Rank)
| Current Allocation
| Value/Total | ROI
| YTD Stock P/L
| Recent Stock P/L
| % Current Price Change for $1,000 P/L
| Symbol (Rank)
| Initial Allocation
| Value/Total | ROI
| YTD Stock P/L
| Recent Stock P/L
| % Current Price Change for $1,000 P/L
| AKYA
| 15.0%
| 8.2% | -27.1%
| -$4,059.56
| $344.83
| 9.1%
| AFMD
| 10%
| 4.6% | -45.9%
| -$5,794.53
| $671.15
| 14.6%
| CRBU
| 5.0%
| 3.7% | 0.3%
| $15.92
| -$764.33
| 19.9%
| CDTX
| 10%
| 11.6% | 37.2%
| $4,696.11
| -$157.49
| 5.8%
| GRPH
| 10.0%
| 5.9% | -20.8%
| -$2,078.31
| -$331.33
| 12.6%
| CLSD
| 10%
| 9.2% | 9.3%
| $1,178.05
| $1,495.65
| 7.2%
| MGTA
| 10.0%
| 14.5% | 94.6%
| $9,460.76
| $655.70
| 5.1%
| CRDF
| 10%
| 8.4% | -0.8%
| -$102.61
| -$355.33
| 8.0%
| MRUS
| 15.0%
| 19.7% | 76.4%
| $11,460.89
| $1,182.93
| 3.8%
| CRIS
| 10%
| 11.5% | 36.7%
| $4,632.49
| -$161.31
| 5.8%
| NAUT
| 10.0%
| 14.2% | 90.0%
| $9,000.00
| -$222.22
| 5.3%
| CRVS
| 10%
| 23.1% | 174.1%
| $21,984.10
| -$1,829.09
| 2.9%
| PACB
| 10.0%
| 12.5% | 68.0%
| $6,797.07
| $1,699.27
| 6.0%
| KZIA
| 10%
| 10.7% | 26.6%
| $3,360.09
| -$3,662.68
| 6.3%
| PSNL
| 15.0%
| 11.4% | 2.0%
| $303.03
| $530.30
| 6.5%
| MGTA
| 10%
| 14.7% | 74.4%
| $9,389.90
| $741.85
| 4.5%
| QSI
| 10.0%
| 9.9% | 32.2%
| $3,224.04
| $2,021.86
| 7.6%
| MRNA
| 10%
| 6.2% | -27.1%
| -$3,420.25
| $188.18
| 10.9%
|
|
|
|
|
|
| PRVB
| 10%
| 0.0% | 136.5%
| $13,651.84
| $0.00
| --
|
|
